Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FRX posted fiscal second quarter EPS of $0.79, beating the Street by $0.03 and up 61% up from $0.49 in the same
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury